Liglifev (Metformin Hydrochloride, Linagliptin)

• Liglifev is used to manage hyperglycemia within the type 2 diabetes mellitus pathway.
• Type 2 diabetes mellitus: improves blood glucose levels when combined with diet and exercise.
• Adjunct therapy in patients inadequately controlled on monotherapy: provides additional glucose‑lowering effect.
• Combination therapy with other antidiabetic agents: enhances overall glycemic control and may reduce need for dose escalation.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby decreasing fasting glucose. Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4, prolonging the activity of endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins stimulate glucose‑dependent insulin release and suppress glucagon secretion, resulting in improved post‑prandial glucose control. The two agents act synergistically to lower overall blood glucose.

Liglifev may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset that may resolve with continued therapy.
• Diarrhea: loose stools occurring especially during treatment initiation.
• Abdominal discomfort: cramping or pain in the stomach area.
• Headache: transient head pain without neurological signs.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate, more likely in renal impairment.
• Severe hypoglycemia: especially when combined with insulin or sulfonylureas, presenting with confusion, sweating, or loss of consciousness.
• Pancreatitis: acute inflammation of the pancreas, characterized by severe abdominal pain and elevated enzymes.

When prescribing Liglifev, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter.
• Hepatic impairment: use with caution in patients with liver disease due to increased risk of lactic acidosis.
• Concomitant alcohol use: advise patients to limit alcohol as it may potentiate metformin‑related lactic acidosis.
• Pregnancy and breastfeeding: safety not established; prescribe only if potential benefit outweighs risk.
• Drug interactions: review concomitant medications that may affect metformin or linagliptin levels.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Liglifev can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase risk of metformin‑associated lactic acidosis.
• Cimetidine: can raise metformin plasma concentrations, heightening toxicity risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or insulin: combined use can enhance hypoglycemia; monitor blood glucose closely.
• Alcohol: excessive intake can augment metformin’s effect on lactate metabolism.
• Diuretics: may affect renal clearance of metformin, necessitating dose adjustment.
• NSAIDs: concurrent use may impair renal function, influencing metformin elimination.